Despite a high number of ongoing clinical trials, this cytokine has not been approved by the FDA to treat patients with cancers, except malignant osteoporosis, possibly because of the contribution of IFNγ to tumor evasion and the induction of adverse events [249]. This evidence concerns the gene IFNG and cancer.